Return to overview

References

1.  DeFronzo RA. From the triumvirate to the ominous octet:
     a new paradigm for the treatment of type 2 diabetes
     mellitus.Diabetes. 2009;58(4):773-795.

2.  DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic
     approach to therapy in patients with newly diagnosed
     type 2 diabetes. Diabetes Care. 2013;36(suppl 2):
     S127-S138.

3.  Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors
     in the brain: controlling food intake and body weight.
     J Clin Invest. 2014;124(10):4223–4226.

4.  Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and
     GIP. Gastroenterology. 2007;132(6):2131–2157.

5.  Bunck MC, Cornér A, Eliasson B, et al. Effects of
     exenatide on measures of ß-cell function after 3
     years in metformin-treated patients with type 2
     diabetes. Diabetes Care. 2011;34(9):2041-2047.

6.  Bunck MC, Diamant M, Cornér A, et al. One-year
     treatment with exenatide improves ß-cell function,
     compared with insulin glargine, in metformin-treated
     type 2 diabetic patients. Diabetes Care. 2009;32(5):
     762-768.

7.  DeFronzo RA, Davidson JA, Del Prato S. The role of the
     kidneys in glucose homeostasis: a new path towards
     normalizing glycaemia. Diabetes Obes Metab. 2012;
     14(1):5-14.

8.  Gibson CD, Carnell S, Ochner CN, Geliebter A.
     Neuroimaging, gut peptides and obesity: novel
     studies of the neurobiology of appetite.
     J Neuroendocrinol. 2010;22(8):833-845.

9.  Holst JJ, Vilsboll T, Deacon CF. The incretin system and its
     role in type 2 diabetes mellitus. Mol Cell Endocrinol.
     2009;297(1-2):127-136.

10. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH.
      Abnormal alpha-cell function in diabetes. Response
      to carbohydrate and protein ingestion. N Engl J Med.
      1970;283(3):109-115.